Where are Cochlear (ASX:COH) shares headed in 2022?

The hearing implant device maker has been a darling of long-term investors for decades. But is the stock too expensive now?

| More on:
An older woman tries to listen by cupping her ear.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Limited (ASX: COH) has been a staple for many ASX share portfolios in the past decade.

The hearing device maker has handsomely rewarded its original investors with a 2,350% return, according to Google Finance, and a 13.8% gain over 2021.

However, this year has ended on a sour note, as the share price actually has fallen more than 14% since its August high.

So where to from here? Is it one to buy for 2022?

'Sales have stagnated'

Redpoint Investment Management chief Max Cappetta told The Motley Fool that "revenue growth has faltered" recently for Cochlear.

"Implant sales have stagnated during the COVID pandemic."

Despite sound business prospects, Cappetta reckons that the valuation is "stretched" at the moment.

"Our metrics do point to a resurgence in revenue growth but this seems to be fully priced in at present," he said.

"While there are improving prospects going forward, there also remains the potential for competing products — though we note that the Cochlear's devices remain clear market leaders."

Cochlear shares are dividing the experts

It seems Cochlear shares are polarising analysts.

The Motley Fool's Zach Bristow reported earlier this month that out of 4 major investment houses, one is bearish, one is neutral and two are slightly bullish on the stock.

Goldman Sachs has set a target of $197 a share, which is about a 10% downside from Wednesday morning's price of $218.18.

"The firm says that Cochlear's surgery volumes remain at risk due to their elective nature. It notes that Australian surgery numbers are yet to recover to pre-pandemic volumes," Bristow reported.

"Goldman Sachs recognises these challenges and reckons Cochlear is a sell in a recent note to clients."

Meanwhile Citi is neutral with a $220 target, while Jarden and Macquarie rate Cochlear as a "buy" with targets of $258 and $256 respectively.

According to CMC Markets, 8 of 12 analysts are recommending a "hold" for Cochlear shares as the year winds down.

Motley Fool contributor Tony Yoo owns Cochlear Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »